Other languages Orphazyme A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 06:47:45 2024-04-29 EDT			5-day change	1st Jan Change
1,090 ^DKK	0.00%		+8.46%	-18.05%

03-27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	23-09-12
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	23-05-30
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-05-30
Orphazyme A/S Announces Board Changes	23-05-17
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-04-25
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-25
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-26
Orphazyme A/S Revises Earnings Guidance for the Year 2022	22-09-25
Orphazyme A/S Announces Board Appointment	22-06-29
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-07
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022	22-06-07
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan	22-06-01
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.	22-05-30
Orphazyme A/S Announces Executive Changes	22-05-23
KemPharm Agrees to Buy Orphazyme for $12.8 Million	22-05-16
Orphazyme's American Depositary Shares Delisted From Nasdaq	22-04-01
European ADRs Move Lower in Wednesday Trading	22-03-23

No results for this search